Edotecarin

Drug Profile

Edotecarin

Alternative Names: ED 749; J-107088; PF-804950; PHA-782615

Latest Information Update: 21 Aug 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Banyu; Merck & Co
  • Class Antineoplastics; Carbazoles; Indoles
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Colorectal cancer; Glioblastoma

Most Recent Events

  • 17 Jan 2006 Discontinued - Phase-III for Glioblastoma in USA (IV-injection)
  • 17 Jan 2006 Data presented at the 13th European Cancer Conference (ECCO-2005) have been added to the Cancer therapeutic trials section
  • 05 Apr 2005 Pfizer has terminated its license for edotecarin worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top